Sökning: onr:"swepub:oai:lup.lub.lu.se:0375add3-30bb-4a65-a0f3-3af80d413f40" >
Pathological comple...
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
-
Bonnefoi, H. (författare)
-
Litiere, S. (författare)
-
Piccart, M. (författare)
-
visa fler...
-
MacGrogan, G. (författare)
-
Fumoleau, P. (författare)
-
Brain, E. (författare)
-
Petit, T. (författare)
-
Rouanet, P. (författare)
-
- Jassem, J. (författare)
- Karolinska Institutet
-
Moldovan, C. (författare)
-
Bodmer, A. (författare)
-
Zaman, K. (författare)
-
Cufer, T. (författare)
-
Campone, M. (författare)
-
Luporsi, E. (författare)
-
- Malmström, Per (författare)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Werutsky, G. (författare)
-
Bogaerts, J. (författare)
-
Bergh, J. (författare)
-
Cameron, D. A. (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2014
- 2014
- Engelska.
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 1569-8041 .- 0923-7534. ; 25:6, s. 1128-1136
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Pathological complete response (pCR) following chemotherapy is strongly associated with both breast cancer subtype and long-term survival. Within a phase III neoadjuvant chemotherapy trial, we sought to determine whether the prognostic implications of pCR, TP53 status and treatment arm (taxane versus non-taxane) differed between intrinsic subtypes. Patients were randomized to receive either six cycles of anthracycline-based chemotherapy or three cycles of docetaxel then three cycles of eprirubicin/docetaxel (T-ET). pCR was defined as no evidence of residual invasive cancer (or very few scattered tumour cells) in primary tumour and lymph nodes. We used a simplified intrinsic subtypes classification, as suggested by the 2011 St Gallen consensus. Interactions between pCR, TP53 status, treatment arm and intrinsic subtype on event-free survival (EFS), distant metastasis-free survival (DMFS) and overall survival (OS) were studied using a landmark and a two-step approach multivariate analyses. Sufficient data for pCR analyses were available in 1212 (65%) of 1856 patients randomized. pCR occurred in 222 of 1212 (18%) patients: 37 of 496 (7.5%) luminal A, 22 of 147 (15%) luminal B/HER2 negative, 51 of 230 (22%) luminal B/HER2 positive, 43 of 118 (36%) HER2 positive/non-luminal, 69 of 221(31%) triple negative (TN). The prognostic effect of pCR on EFS did not differ between subtypes and was an independent predictor for better EFS [hazard ratio (HR) = 0.40, P < 0.001 in favour of pCR], DMFS (HR = 0.32, P < 0.001) and OS (HR = 0.32, P < 0.001). Chemotherapy arm was an independent predictor only for EFS (HR = 0.73, P = 0.004 in favour of T-ET). The interaction between TP53, intrinsic subtypes and survival outcomes only approached statistical significance for EFS (P = 0.1). pCR is an independent predictor of favourable clinical outcomes in all molecular subtypes in a two-step multivariate analysis.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- breast cancer
- neoadjuvant chemotherapy
- TP53
- landmark analysis
- pathological complete response
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bonnefoi, H.
-
Litiere, S.
-
Piccart, M.
-
MacGrogan, G.
-
Fumoleau, P.
-
Brain, E.
-
visa fler...
-
Petit, T.
-
Rouanet, P.
-
Jassem, J.
-
Moldovan, C.
-
Bodmer, A.
-
Zaman, K.
-
Cufer, T.
-
Campone, M.
-
Luporsi, E.
-
Malmström, Per
-
Werutsky, G.
-
Bogaerts, J.
-
Bergh, J.
-
Cameron, D. A.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Lunds universitet
-
Karolinska Institutet